“…In allotransplantation, there is now significant research on organ-specific mechanisms contributing to IRI, and IRIM strategies ( 23 , 24 , 40 , 41 , 66 , 165 , 227 ). Current research in IRIM for heart, lungs, kidney, and liver allografts include reducing the effects of ROS, and directly or indirectly inhibiting inflammatory mediators, complement, immune cell platelet adhesion and activation, and maintaining, preserving, or restoring endothelial barrier and vasoregulatory functions ( 23 , 41 , 50 , 52 , 114 , 190 , 227 – 265 ). Promising findings in reduction of lung IRI have included adenosine A2A receptor activation reducing microvascular permeability and lung injury, early growth response 1 (Egr1) deletion reducing neutrophil infiltration, C3a receptor antagonist decreasing cell injury and inflammation, carbon monoxide in cold flush reducing inflammatory mediators and cellular infiltrate, and nitric oxide to reduce pulmonary arterial pressures, inflammation, and apoptosis ( 50 , 52 , 190 , 266 – 269 ).…”